{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:35:52Z","timestamp":1791668152798,"version":"4.3.4"},"reference-count":33,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J cachexia sarcopenia muscle"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Appetite loss is a common and distressing symptom in non\u2010small\u2010cell lung cancer (NSCLC), driven by both treatment side effects and disease progression. It often leads to unintended weight loss and cancer cachexia, significantly impairing patients' quality of life and survival. Yet, appetite loss remains under\u2010recognized in oncology care, with no standard assessment tools or universal management guidelines. In this study, we developed a predictive model to identify clinically meaningful thresholds of appetite loss that were associated with significant weight reduction and decreased survival. We aim to highlight the clinical consequences of appetite loss and advocate for more patient\u2010centred treatment strategies that address this often overlooked but impactful symptom in cancer care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We analysed longitudinal patient\u2010reported appetite scores, measured by the Lung Cancer Symptom Scale (LCSS), and body weight data from 476 NSCLC patients receiving supportive care and recovering from prior chemoradiotherapy (recovering cohort). A mechanism\u2010based population modelling approach was used to predict the impact of appetite changes on body weight, accounting for significant data variability. Model validation was conducted using data from 380 NSCLC patients undergoing docetaxel chemotherapy (chemotherapy cohort). Clinically meaningful appetite loss thresholds were determined based on the model\u2010predicted appetite loss associated with a 3.5\u2010kg body weight loss and significantly worse survival (hazard ratio\u2009&gt;\u20091,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We found that, according to the LCSS (100\u2010mm visual analogue scale), a 30\u2010mm (90% CI, 28\u201332) improvement in appetite corresponded to a 3.5\u2010kg weight gain in the recovering cohort, while a 23\u2010mm (90% CI, 17\u201330) decline correlated with a 3.5\u2010kg weight loss in the chemotherapy cohort. Significant associations were observed between appetite loss trajectories and overall survival (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Clinically meaningful thresholds for appetite loss were identified as 4\u2009mm at 1\u2009month and 11\u2009mm at 3\u2009months, both significantly associated with reduced OS in patients receiving docetaxel chemotherapy (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We developed a population predictive model to characterize the relationship between patient\u2010reported appetite and body weight, identifying clinically meaningful thresholds for appetite loss. This work highlights the importance of managing appetite loss in oncology care and supports its use as a quantitative endpoint in clinical trials and practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jcsm.70150","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:20:26Z","timestamp":1764807626000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["From Symptom to Outcome: Defining Clinically Meaningful Patient\u2010Reported Appetite Loss in Non\u2010Small\u2010Cell Lung Cancer"],"prefix":"10.1002","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3317-0311","authenticated-orcid":false,"given":"Jiawei","family":"Zhou","sequence":"first","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy University of North Carolina at Chapel Hill  Chapel Hill North Carolina USA"},{"name":"Lineberger Comprehensive Cancer Center, School of Medicine University of North Carolina at Chapel Hill  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benyam","family":"Muluneh","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy University of North Carolina at Chapel Hill  Chapel Hill North Carolina USA"},{"name":"Lineberger Comprehensive Cancer Center, School of Medicine University of North Carolina at Chapel Hill  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quefeng","family":"Li","sequence":"additional","affiliation":[{"name":"Gillings School of Global Public Health University of North Carolina at Chapel Hill  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne\u00a0I.","family":"Wagner","sequence":"additional","affiliation":[{"name":"Gillings School of Global Public Health University of North Carolina at Chapel Hill  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Wang","sequence":"additional","affiliation":[{"name":"Pfizer Inc  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim\u00a0H.","family":"Hughes","sequence":"additional","affiliation":[{"name":"Pfizer Inc  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"10","article-title":"Cancer Statistics, 2025","volume":"75","author":"Siegel R. L.","year":"2025","journal-title":"Ca"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.4932"},{"key":"e_1_2_6_4_1","first-page":"1023","article-title":"Quality of Life of Patients With Lung Cancer","volume":"9","author":"Polanski J.","year":"2016","journal-title":"Oncotargets and Therapy"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.2196\/44105"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.13186"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12528"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.appet.2017.03.020"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2008.08.014"},{"key":"e_1_2_6_10_1","unstructured":"Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases Draft Guidance for Industry U.S. Food & Drug Administration.https:\/\/www.fda.gov\/media\/164555\/download. accessed December 19 2024."},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.5566"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp386"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-4073"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-0292"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70510-2"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.6932"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s005200050244"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940415)73:8<2087::AID-CNCR2820730813>3.0.CO;2-X"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(05)80262-X"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.1.19"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.155"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2012.4"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12451"},{"key":"e_1_2_6_24_1","first-page":"106","article-title":"Model Evaluation in Nonlinear Mixed Effect Models, With Applications to Pharmacokinetics","volume":"151","author":"Comets E.","year":"2010","journal-title":"Journal de la Soci\u00e9t\u00e9 Fran\u00e7aise de Statistique"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12161"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70218-7"},{"key":"e_1_2_6_27_1","unstructured":"Project Data Sphere.https:\/\/data.projectdatasphere.org\/projectdatasphere\/html\/home. accessed May 21 2025."},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-013-9318-0"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.10.029"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101418"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2020.07.020"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153860"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36121-y"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-3665"}],"container-title":["Journal of Cachexia, Sarcopenia and Muscle"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcsm.70150","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcsm.70150","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcsm.70150","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T08:41:46Z","timestamp":1772959306000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcsm.70150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1002\/jcsm.70150"],"URL":"https:\/\/doi.org\/10.1002\/jcsm.70150","archive":["Portico"],"relation":{},"ISSN":["2190-5991","2190-6009"],"issn-type":[{"value":"2190-5991","type":"print"},{"value":"2190-6009","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"2025-07-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70150"}}